Lipitor vs Crestor: Cost, Access, and Clinical Value Compared

Why This Comparison Matters in 2026

Statins remain the most prescribed drug class in the United States. Over 92 million American adults filled a statin prescription in 2023, and atorvastatin alone has held the title of the single most dispensed medication in the country for more than a decade, according to ClinCalc drug utilization data. Rosuvastatin ranks in the top five.

Both molecules are now available as inexpensive generics, which makes pure price comparisons less dramatic than they were a decade ago. But "cheap" does not mean "identical cost." Formulary tier placement, copay structure, quantity limits, and step-therapy requirements still create meaningful gaps in what patients actually pay. A 2022 JAMA Internal Medicine analysis found that out-of-pocket statin costs varied by as much as 400% across Medicare Part D plans for the same molecule and dose 1. That variation drives real-world adherence. And adherence, not potency on paper, is what determines whether a statin prevents a heart attack.

The sections below break down potency, price, formulary access, drug interactions, and trial evidence so you can work with your prescriber to pick the statin that fits your clinical profile and your budget.

LDL-Lowering Potency: Rosuvastatin Wins on Paper

Rosuvastatin produces greater LDL reduction per milligram than atorvastatin across every dose tier. The 2018 ACC/AHA cholesterol guideline classifies both as "high-intensity" statins at their top doses, but the numbers are not identical 2.

High-intensity statin therapy is defined as a regimen expected to lower LDL-C by 50% or more. Atorvastatin 40 to 80 mg meets this threshold. Rosuvastatin reaches it at 20 to 40 mg. In the STELLAR trial (N=2,431), rosuvastatin 10 mg reduced LDL by 45.8%, while atorvastatin required 20 mg to reach a comparable 42.6% reduction across the dose-ranging protocol 3. That gap grows at higher doses. Rosuvastatin 40 mg achieved a 55.0% LDL reduction compared to 51.1% for atorvastatin 80 mg in the same study.

Does that 3 to 5 percentage-point gap matter clinically? It depends. For a patient whose baseline LDL is 190 mg/dL and who needs to reach a target below 70 mg/dL after an acute coronary syndrome, those extra percentage points could be the difference between reaching goal on a statin alone or needing add-on ezetimibe. For a primary prevention patient with baseline LDL of 145 mg/dL, both drugs will comfortably hit most targets.

The 2018 ACC/AHA guideline states: "For patients with clinical ASCVD who are judged to be very high risk, use a maximally tolerated statin" 2. It does not express a preference between the two molecules.

Landmark Trial Evidence: Different Populations, Consistent Benefit

No large randomized trial has compared atorvastatin head-to-head against rosuvastatin for hard cardiovascular outcomes (myocardial infarction, stroke, cardiovascular death). The strongest evidence for each drug comes from separate placebo-controlled trials run in different populations.

Atorvastatin: ASCOT-LLA. This trial randomized 10,305 hypertensive patients with at least three additional cardiovascular risk factors to atorvastatin 10 mg or placebo. The trial was stopped early at a median of 3.3 years because the atorvastatin group showed a 36% relative reduction in coronary heart disease events (HR 0.64 to 95% CI 0.50 to 0.83, P = 0.0005) 4. The absolute risk reduction translated to a number needed to treat (NNT) of approximately 91 over 3.3 years for primary prevention.

Rosuvastatin: JUPITER. This trial enrolled 17,802 apparently healthy men (age 50+) and women (age 60+) with LDL cholesterol <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher. Rosuvastatin 20 mg reduced the primary composite endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death by 44% compared to placebo (HR 0.56 to 95% CI 0.46 to 0.69, P <0.00001) 5. The trial was also stopped early, at a median of 1.9 years.

These results cannot be directly compared. JUPITER enrolled a lower-LDL, higher-inflammation cohort and used a higher statin dose relative to ASCOT-LLA. The larger relative risk reduction in JUPITER likely reflects both the potency advantage of rosuvastatin 20 mg over atorvastatin 10 mg and the specific biology of the hsCRP-selected population.

A 2015 Cochrane systematic review of statins for primary prevention (18 trials, 56,934 participants) concluded that statins as a class reduce all-cause mortality by about 14% (OR 0.86 to 95% CI 0.79 to 0.94) without distinguishing between molecules 6.

Generic Pricing: Both Are Cheap, but Atorvastatin Is Usually Cheaper

Atorvastatin lost patent protection in November 2011. Rosuvastatin followed in January 2016. Both generics flooded the market quickly.

As of early 2026, GoodRx cash-price data shows the following ranges for a 30-day supply at major U.S. chain pharmacies: atorvastatin 20 mg runs $3 to $8, while rosuvastatin 10 mg (a pharmacologically comparable dose) runs $4 to $12. At maximum doses, atorvastatin 80 mg costs $4 to $10 and rosuvastatin 40 mg costs $7 to $15. The price gap narrows when pharmacy discount programs are applied. Walmart, Costco, and Mark Cuban's Cost Plus Drugs all list both molecules under $10 for a 90-day supply at common doses.

For insured patients, the out-of-pocket difference is usually the copay tier. A 2023 analysis of Medicare Part D formularies found that 94% of plans placed atorvastatin on Tier 1 (preferred generic, typical copay $0 to $5) compared to 81% for rosuvastatin 7. The remaining plans listed rosuvastatin on Tier 2 (non-preferred generic, typical copay $8 to $15). This difference is shrinking year over year as rosuvastatin's generic market matures, but it has not vanished.

Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic, noted in a 2020 interview: "When two drugs in the same class are both generic and both effective, the one that is easier for the patient to obtain and afford is the better drug for that patient."

Insurance Formulary Access and Step Therapy

Most commercial insurers and Medicare Part D plans cover both molecules without prior authorization. The practical access differences show up in three areas.

Step therapy. Some plans require a trial of atorvastatin before covering rosuvastatin. This is uncommon in 2026 but still exists on a handful of tightly managed Medicaid and employer-sponsored plans. If your prescriber writes for rosuvastatin and the pharmacy rejects the claim, the fix is typically a peer-to-peer call or a formulary exception request documenting a clinical reason (such as a CYP3A4 drug interaction that makes atorvastatin inappropriate).

Quantity limits. Both drugs are dosed once daily, so quantity limits rarely create problems. Some plans cap at 30 tablets per fill; others allow 90-day supplies. Patients paying cash should always request 90-day fills, as the per-tablet cost drops.

Specialty pharmacy routing. Neither atorvastatin nor rosuvastatin is routed through specialty pharmacies. This is worth noting because some newer lipid-lowering agents (PCSK9 inhibitors, bempedoic acid) do require specialty channels, adding logistical friction. Statins remain the most pharmacy-accessible lipid drugs available.

For Medicaid patients, both statins are on every state's preferred drug list, though the preferred agent varies by state. A 2021 AHRQ review of state Medicaid formularies found atorvastatin was the preferred statin in 34 states and rosuvastatin in 11, with the remaining states listing both without preference.

Drug Interactions: A Clinically Important Difference

This is where the two molecules diverge in a way that matters beyond cost. Atorvastatin is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme. Rosuvastatin undergoes minimal CYP metabolism and is eliminated largely unchanged via bile 8.

The practical result: atorvastatin interacts with a long list of commonly prescribed drugs that inhibit CYP3A4. These include clarithromycin, itraconazole, ketoconazole, ritonavir-boosted HIV protease inhibitors, and even large quantities of grapefruit juice. Co-administration raises atorvastatin blood levels and increases the risk of myopathy and rhabdomyolysis. The FDA label for atorvastatin carries specific dose caps when used with several of these agents 9.

Rosuvastatin, by contrast, has fewer pharmacokinetic interactions. Its main interaction concern is with cyclosporine and certain antivirals (such as the combination of atazanavir and ritonavir), which can raise rosuvastatin levels through transporter-mediated mechanisms rather than CYP inhibition 10.

For patients on multiple medications (polypharmacy is common in the cardiometabolic population), rosuvastatin may offer a simpler interaction profile. This is one of the strongest clinical reasons to choose rosuvastatin over atorvastatin independent of cost.

Side Effects and Tolerability

Both statins share the same class-wide side-effect profile: muscle pain (myalgia), elevated liver enzymes, gastrointestinal upset, and a modest increase in the risk of new-onset type 2 diabetes. Short sentences first. Serious myopathy is rare. Rhabdomyolysis is rarer still.

The JUPITER trial reported a statistically significant increase in physician-reported diabetes with rosuvastatin 20 mg compared to placebo (3.0% vs 2.4%, P = 0.01) 5. A 2010 meta-analysis of 13 statin trials (91,140 participants) found that statin therapy of any type was associated with a 9% increased risk of incident diabetes (OR 1.09 to 95% CI 1.02 to 1.17), with higher-intensity regimens carrying slightly greater risk 11. The absolute risk increase is small (roughly 1 additional case of diabetes per 255 patients treated for 4 years), and the cardiovascular benefit consistently outweighs the diabetes risk in populations for whom statins are indicated.

Regarding muscle symptoms, a 2022 SAMSON trial (N=200) and the larger StatinWISE trial (N=200 per arm) both demonstrated that most patient-reported muscle symptoms attributed to statins are not caused by the statin molecule itself. The nocebo effect accounts for the majority of reported myalgia in blinded conditions 12. Neither atorvastatin nor rosuvastatin showed a significantly different rate of true statin-attributable muscle symptoms in these studies.

The American Heart Association's 2022 scientific statement on statin-associated muscle symptoms affirmed: "Clinicians should reassure patients that true statin-associated muscle symptoms are uncommon, and that the cardiovascular benefits of statin therapy substantially outweigh the risks in appropriately selected patients" 13.

Who Should Pick Which Statin

The decision tree is simpler than most comparison articles suggest.

Choose atorvastatin when: your insurance plan places it on Tier 1 and rosuvastatin on Tier 2, you have no significant CYP3A4 drug interactions, and your LDL goal is achievable with atorvastatin 40 or 80 mg. Atorvastatin is also the default in many electronic health record order sets simply because of its longer generic history and marginally lower average cost.

Choose rosuvastatin when: you take medications that inhibit CYP3A4 (check with your pharmacist), you need maximal LDL lowering and are already on or near the top atorvastatin dose without reaching goal, or your plan prices both generics equally and you prefer the slightly lower starting dose needed.

Either drug works well when: you are starting statin therapy for primary prevention with moderate cardiovascular risk, your LDL target is achievable with either molecule at standard doses, and neither drug interaction profile is a concern.

A reasonable first step for any patient is to ask the pharmacist to run both drugs through their insurance before filling. The price difference, if any, is visible in real time.

Switching Between the Two Statins

Switching from atorvastatin to rosuvastatin (or vice versa) is straightforward and does not require a washout period. The ACC/AHA guideline does not mandate repeat lipid testing before a switch, but most clinicians will recheck a fasting lipid panel 4 to 12 weeks after the change to verify the new dose achieves the LDL target 2.

Dose-equivalence conversion is well established. Atorvastatin 10 mg is roughly equivalent to rosuvastatin 5 mg. Atorvastatin 20 mg maps to rosuvastatin 10 mg. Atorvastatin 40 mg maps to rosuvastatin 20 mg. Atorvastatin 80 mg is closest to rosuvastatin 40 mg, though rosuvastatin 40 mg produces slightly greater LDL reduction as noted above 3.

Common reasons prescribers initiate a switch include: a change in insurance formulary status, a new co-prescribed medication that creates a CYP3A4 interaction with atorvastatin, failure to reach LDL goal on the maximum tolerated dose of one agent, or patient-reported side effects that the clinician suspects may resolve with a different statin molecule (though the evidence for this is limited).

What the Guidelines Say

The 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol does not recommend one statin over another within the same intensity category 2. The guideline's core recommendations are organized around four statin-benefit groups: clinical ASCVD, severe hypercholesterolemia (LDL 190+ mg/dL), diabetes in adults 40 to 75, and primary prevention with 10-year ASCVD risk of 7.5% or higher.

Within each group, the guideline specifies high-intensity or moderate-intensity therapy. The prescriber then selects a specific molecule and dose. Cost, formulary access, interaction profile, and patient preference all factor into that selection, exactly the variables this article addresses.

The Endocrine Society's 2020 guideline on lipid management in endocrine disorders similarly treats atorvastatin and rosuvastatin as interchangeable within intensity tiers, noting only that "rosuvastatin may be preferred when drug-drug interactions limit atorvastatin dosing" 14.

Both drugs carry an FDA pregnancy category X designation and are contraindicated in pregnancy and breastfeeding. Neither should be prescribed to patients with active liver disease or unexplained persistent elevations of serum transaminases.

The Bottom Line on Cost and Access in 2026

For most patients in 2026, the out-of-pocket difference between generic atorvastatin and generic rosuvastatin is $0 to $10 per month. Atorvastatin holds a slight edge in Tier 1 formulary prevalence, while rosuvastatin holds a slight edge in LDL-lowering potency and drug interaction simplicity. Ask your pharmacist to price-check both before filling, and discuss your full medication list with your prescriber to rule out CYP3A4 conflicts. A fasting lipid panel 6 to 8 weeks after starting or switching confirms you have reached your LDL target.